Pfizer Shares Quiet; STAT News Reports ‘Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens’
https://www.statnews.com/pharmalot/2021/06/24/pfizer-chantix-champix-smoking-nitrosamines/
Evolus Highlights Peer-Reviewed Article On Efficacy, Safety Of Its Jeuveau In Patients With Skin Of Color
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a peer reviewed journal article was published in Dermatologic Surgery
Aquestive Therapeutics Reports Resubmission Of New Drug Application For Libervant Buccal Film
Anticipates FDA PDUFA goal date in late 2021
If approved by the FDA for US market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters
WARREN, N.J., June
The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
VectivBio Holding AG, ("Vectiv" or "VectivBio") (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for
Alnylam Announces FDA Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug and Administration ("FDA") has maintained Priority Review for the
Lilly’s Donanemab Receives U.S. FDA’s Breakthrough Therapy Designation For Treatment Of Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE:LLY) investigational antibody therapy for Alzheimer's disease (AD). The
Where Might Entera Bio Stock End Up After Rallying Wednesday
Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinical trial of EB613 for osteoporosis.